Across TCGA pan-cancer cohorts, PRPF39 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPF39 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRPF39 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRPF39 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where PRPF39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.985	0.067	.008	30	view →
PDAC	OS	Quartile	II,III,IV	0.294	0.483	.019	9	view →
HNSC	OS	Tertile	All	0.640	0.843	.036	7	view →
GBM	OS	Tertile	All	0.475	0.257	.012	6	view →
LUAD	OS	Median	II,III,IV	0.999	0.863	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PRPF39 tumor-vs-normal RNA expression · all PRPF39 data types